LGBTQ-affirmative CBT: 16-session LGBTQ-affirmative psychotherapy using cognitive behavioral techniques
ABFT-SGM: 16-session attachment-based family therapy for sexual and gender minority young adults and their nonaccepting parents
Study summary
The purpose of this study is to assess the efficacy of an LGBTQ-affirmative individual cognitive behavioral psychotherapy (CBT) and LGBTQ-affirmative family therapy (attachment-based family therapy for sexual and gender minority young adults; ABFT-SGM) delivered via telehealth to a sample of sexual and gender minority adults with nonaccepting parent(s) in New York, Pennsylvania, Connecticut, and Israel. The investigators will assess whether both treatments are associated with significant decreases in depressive and anxiety symptoms. The investigators will also assess whether and how each treatment achieves reductions in mental health symptoms through specific mechanisms (e.g., rejection sensitivity, internalized stigma, emotion dysregulation, parental rejection and acceptance).
Eligibility
Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* be 20 and older
* be fluent in English
* self-identify as lesbian, bisexual, queer, pansexual, or other non-heterosexual identity
* currently experience elevated depressive or anxiety symptoms (screened initially using a cutoff of ≥ 2.5 on the Brief Symptom Inventory-4 and further confirmed by the BDI and BAI).
* report at least moderate levels of parental rejection or low levels of parental acceptance, as measured using the PARSOS.
* have at least one rejecting/nonaccepting parent that agrees to participate in the therapy.
* live in New York State, Pennsylvania, Connecticut, or Israel.
Exclusion Criteria:
* report current mental health treatment ≥1 day/month (except for medication management ≤1 day/week)
* report beginning a new medication within the past 30 days
* exhibit active psychosis or active mania, as assessed by the SCID-Psych Screen.
* exhibit active suicidality or active homicidality, as assessed by the SIDAS
* be currently legally mandated to attend treatment
* demonstrate gross cognitive impairment, as assessed with the Telephone Interview for Cognitive Status
* do not have a parent willing to participate
Primary outcome measure(s)
Change in depression symptoms — Baseline, Immediate Post-intervention, 5-month Post-intervention Depressive symptoms will be measured using the 21-item Beck Depression Inventory-II (BDI). Items are rated on a scale from 0-3 where higher scores indicate greater depression symptoms, with a maximum score of 63.
Change in anxiety symptoms — Baseline, Immediate Post-intervention, 5-month Post-intervention Anxiety symptoms will be measured using the 21-item Beck Anxiety Inventory (BAI). Items are rated on a scale from 0-3 where higher scores indicate greater anxiety symptoms, with a maximum score of 63.
Trial sites (2)
Facility
City
Region
Status
Yale LGBTQ Mental Health Initiative with the Yale School of Public Health Office
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
